Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell Transplantation

被引:0
作者
Xu Tan
Xiao-qi Wang
Cheng Zhang
Xian-lan Zhao
Han Yao
Guo Chen
Ying-ying Ma
Qin Wen
Lei Gao
Li Gao
Pei-yan Kong
Yan Shen
Xi Zhang
Shi-feng Lou
机构
[1] The Second Affiliated Hospital of Chongqing Medical University,Department of Hematology
[2] Army Medical University,Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burns and Cobmined Injury
[3] Jinfeng Laboratory,undefined
来源
Current Medical Science | 2023年 / 43卷
关键词
CD19-positive B-cell acute lymphoblastic leukemia; relapse; donor-derived CD19 chimeric antigen receptor T cells; chemo-donor lymphocyte infusion;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:733 / 740
页数:7
相关论文
共 101 条
[1]  
Rosko A(2017)Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia Am J Hematol 92 42-49
[2]  
Wang HL(2022)Relapse of acute leukemia after a second allogeneic stem-cell transplantation; Is there any hope for cure? Bone Marrow Transplant 57 336-337
[3]  
de Lima M(1997)Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation J Clin Oncol 15 433-444
[4]  
Shimoni A(2012)Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation Blood 120 2032-2041
[5]  
Collins RHJ(2014)HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation Biol Blood Marrow Transplant 20 314-318
[6]  
Shpilberg O(2015)DLI after haploidentical BMT with post-transplant CY Bone Marrow Transplant 50 56-61
[7]  
Drobyski WR(2016)CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia Clin Adv Hematol Oncol 14 802-808
[8]  
Gökbuget N(2016)Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells J Clin Invest 126 3363-3376
[9]  
Stanze D(2016)Toxicities of chimeric antigen receptor T cells: recognition and management Blood 127 3321-3330
[10]  
Beck J(2016)CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date Blood 127 3312-3320